EyeBio Announces First Asset in Innovative Pipeline of Retinal Disease Treatments and Appoints Industry Leaders to Executive Team

LONDON & NEW YORK--(BUSINESS WIRE)--Eyebiotech Limited (EyeBio), a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to patients with sight-threatening eye diseases, today announced several appointments to its executive team, featuring prominent industry leaders who are highly skilled in the development of multi-specific antibodies and ophthalmic drugs. The Company also announced details on Restoret™, the first asset in a div